Extreme thrombocytosis with an aggressive evolution harboring a novel variant of calreticulin ( CALR ) in exon 3
European Journal of Haematology · 2024
DOI: 10.1111/ejh.14126 ↗Kurz gefasst
Fallbericht in der Zeitschrift European Journal of Haematology, 2024. Verfasst von Sarah Bonnet und 12 weiteren Autor:innen. Beteiligte Einrichtung: Département d'Hématologie Clinique, CHRU Montpellier, Montpellier, France. Hauptthemen laut MEDLINE: Thrombocytosis, Primary Myelofibrosis, Myelodysplastic-Myeloproliferative Diseases, Myeloproliferative Disorders. Die Arbeit nennt 5 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
We describe the case of a patient with extreme thrombocytosis whose evolution was rapidly fatal. No cause of secondary thrombocytosis was found. There was no sign of myelofibrosis but the megakaryocytes were small and dysplastic. The patient presented a calreticulin (CALR) variant in exon 3 (C105S), as well as concomitant mutations of ASXL1, U2AF1, and EZH2. This variant of CALR has never been described before, and after sorting, all identified mutations were found in myeloid cells but not in lymphoid cells. Therefore, the diagnosis of a frontier case of myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) was made. A treatment with hydroxycarbamide was started because of a high risk of thrombosis. Upon worsening of the hematological status two new mutations appeared, SETBP1 and ETV6, and the CALR mutation was still detectable, as well as the three other mutations found in the chronic stage. Our results show that this variant could contribute to MDS/MPN pathogenesis in that patient.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Département d'Hématologie Clinique, CHRU Montpellier, Montpellier, France.
- Département d'Hématologie biologique, Laboratoire de Cytologie Clinique et Cytogénétique, CHRU Nîmes, Nîmes, France.
- IBMM, Univ Montpellier, CNRS, ENSCM, Montpellier, France.
- Centre de Recherche des Cordeliers, Sorbonne Université, Inserm, UMRS 1138, Université de Paris Cité, Paris, France.
- Department of Pathology Assistance Publique-Hôpitaux de Paris (APHP), Hôpital Cochin, Paris, France.
- Institut de Génétique Humaine, UMR 9002 CNRS-UM, Montpellier, France.
ORCID-Profile: Sarah Bonnet, Serge Carillo, Baptiste Legrand, Ahmed Al Mansoori, Jérôme Moreaux, Guillaume Cartron, Ludovic Gabellier, Charles Herbaux
Zitieren
APA
Bonnet, S., Carillo, S., Legrand, B., Burroni, B., Lavabre-Bertrand, T., Requirand, G., Robert, N., Fornero, L., Al Mansoori, A., Moreaux, J., Cartron, G., Gabellier, L., & Herbaux, C. (2024). Extreme thrombocytosis with an aggressive evolution harboring a novel variant of calreticulin ( CALR ) in exon 3. European Journal of Haematology. https://doi.org/10.1111/ejh.14126
Vancouver
Bonnet S, Carillo S, Legrand B, Burroni B, Lavabre-Bertrand T, Requirand G, et al. Extreme thrombocytosis with an aggressive evolution harboring a novel variant of calreticulin ( CALR ) in exon 3. European Journal of Haematology. 2024. doi:10.1111/ejh.14126
BibTeX
@article{Bonnet2024,
author = {Bonnet, Sarah and Carillo, Serge and Legrand, Baptiste and Burroni, Barbara and Lavabre-Bertrand, Thierry and Requirand, Guilhem and Robert, Nicolas and Fornero, Lea and Al Mansoori, Ahmed and Moreaux, Jérôme and Cartron, Guillaume and Gabellier, Ludovic and Herbaux, Charles},
title = {Extreme thrombocytosis with an aggressive evolution harboring a novel variant of calreticulin ( CALR ) in exon 3},
journal = {European Journal of Haematology},
year = {2024},
doi = {10.1111/ejh.14126}
}
EUVIMED